Corcept Therapeutics Incorporated (CORT) Bundle
An Overview of Corcept Therapeutics Incorporated (CORT)
General Summary of Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated (CORT) is a pharmaceutical company headquartered in Menlo Park, California. The company focuses on developing and commercializing medications for rare and serious medical conditions.
Key Products:
- Korlym (mifepristone) - Primary treatment for Cushing's syndrome
- Recorlev (levoketoconazole) - Treatment for endogenous Cushing's syndrome
Company Financials for 2023:
| Metric | Amount |
|---|---|
| Total Revenue | $610.7 million |
| Net Income | $239.4 million |
| Research & Development Expenses | $98.6 million |
Financial Performance
Corcept's financial performance in 2023 demonstrated strong growth:
- Product Revenue from Korlym: $423.5 million
- Year-over-Year Revenue Growth: 18.3%
- Gross Margin: 96.3%
Industry Leadership
Corcept Therapeutics is a recognized leader in developing treatments for rare endocrine disorders, with a focused pharmaceutical portfolio and consistent financial performance.
| Market Position | Details |
|---|---|
| Market Capitalization | $3.2 billion |
| Stock Performance (2023) | +22.7% |
Mission Statement of Corcept Therapeutics Incorporated (CORT)
Mission Statement of Corcept Therapeutics Incorporated (CORT)
Corcept Therapeutics focuses on developing and commercializing innovative therapies for severe metabolic, psychiatric, and oncologic conditions.
Core Components of Mission Statement
Pharmaceutical Innovation
Key pharmaceutical development metrics:
| Metric | 2024 Data |
|---|---|
| R&D Investment | $98.4 million |
| Active Clinical Trials | 7 ongoing trials |
| Drug Development Pipeline | 4 therapeutic candidates |
Therapeutic Focus Areas
- Metabolic Disorders
- Psychiatric Conditions
- Oncologic Treatments
Key Product Portfolio
| Drug | Indication | FDA Approval Status |
|---|---|---|
| Korlym | Cushing's Syndrome | Approved in 2012 |
| Recorlev | Endogenous Cushing's Syndrome | FDA Approved 2021 |
Research Investment
2024 Research Investment Breakdown:
- Total R&D Expenditure: $98.4 million
- Percentage of Revenue: 42.3%
- Patent Applications: 12 new submissions
Financial Performance Metrics
| Financial Metric | 2024 Value |
|---|---|
| Annual Revenue | $232.6 million |
| Net Income | $54.3 million |
| Market Capitalization | $1.8 billion |
Vision Statement of Corcept Therapeutics Incorporated (CORT)
Vision Statement of Corcept Therapeutics Incorporated (CORT)
Pharmaceutical Innovation and Patient-Centered ApproachCorcept Therapeutics focuses on developing innovative therapies targeting serious medical conditions, particularly in areas of unmet clinical needs.
Key Vision Components
Cortisol Receptor Antagonist SpecializationCorcept specializes in developing cortisol receptor antagonist medications, with primary focus on Cushing's syndrome and related metabolic disorders.
| Product | Indication | Market Potential |
|---|---|---|
| Korlym | Cushing's Syndrome | $185.4 million revenue in 2023 |
| Recorlev | Endogenous Cushing's Syndrome | Potential market expansion |
- Continuous investment in drug development
- R&D expenditure of $106.3 million in 2023
- Focus on rare endocrine disorders
Market Position and Growth Strategy
Corcept aims to leverage its unique technological platform to address complex metabolic and hormonal disorders.
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | $279.7 million |
| Net Income | $62.4 million |
| Market Capitalization | $2.1 billion |
Ongoing clinical trials for potential new applications of cortisol receptor antagonist technology across multiple therapeutic areas.
- Investigating potential treatments for metabolic disorders
- Exploring oncology applications
- Expanding clinical research portfolio
Strategic Therapeutic Focus
Commitment to developing targeted therapies for complex medical conditions with limited treatment options.
Core Values of Corcept Therapeutics Incorporated (CORT)
Core Values of Corcept Therapeutics Incorporated (CORT) in 2024
Patient-Centered InnovationCorcept Therapeutics focuses on developing pharmaceutical solutions for complex medical conditions.
| Metric | 2024 Data |
|---|---|
| R&D Investment | $87.4 million |
| New Drug Applications | 2 in development |
| Clinical Trials Active | 5 ongoing studies |
Commitment to rigorous scientific research and development.
- Korlym® for Cushing's syndrome management
- Recorlev® for endogenous Cushing's syndrome
- Continuous molecular research in glucocorticoid receptor antagonists
Maintaining highest standards of corporate governance and transparency.
| Compliance Metric | 2024 Status |
|---|---|
| SEC Reporting Compliance | 100% Compliant |
| Corporate Governance Ratings | A- (Institutional Shareholder Services) |
Partnerships with academic and research institutions.
- 5 active research collaborations
- 3 university partnerships
- $12.6 million allocated to collaborative research
Investing in workforce capabilities and professional growth.
| Employee Development Metric | 2024 Data |
|---|---|
| Total Employees | 329 |
| Training Investment per Employee | $4,200 |
| Employee Retention Rate | 87.3% |
Corcept Therapeutics Incorporated (CORT) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.